Open to Alumni, Open to Community, Open to Faculty, Open to Staff, Open to Students
William Cooper, MD, MPH, is an internationally-recognized leader in pharmacoepidemiology and medication safety. He has had numerous high-impact publications in journals such as the New England Journal of Medicine and JAMA, including a landmark paper in the New England Journal of Medicine describing the association between ACE inhibitors during pregnancy and the risk for major congenital malformations in infants whose mothers took these medications during pregnancy.
Cooper’s work has influenced global health policy, including medication labeling by HealthCanada, the US Food and Drug Administration, and the UK MHRA. The Agency for Healthcare Research and Quality released a special Request for applications for further study of the issue of ACE inhibitor use during pregnancy. By influencing practice in this way, Cooper’s work has reduced the likelihood that children will experience entirely preventable major malformations. Cooper serves on the Drug Safety and Risk Management Advisory Committee for the Food and Drug Administration, where he provides important input into drug safety decisions by the Agency.